ALSO NOTED: Byetta data backs stand-alone app; Watson, Novartis settle suit;

> Amylin Pharmaceuticals says it has the data to back an application to make Byetta a stand-alone therapy for diabetes. Report

> Watson and Novartis have settled their patent wrangle over the Alzheimer's drug Exelon. Report

> We're happy the way we are, thank you very much. That's what Genzyme CEO Henri Termeer (photo) has to say to rumors that the company could be next on the list of Big pharma biotech buyouts. Report

> In yet another sign of monoclonal antibodies' popularity among big drug developers, Wyeth has extend its evaluation of selected Raven Biotechnologies MAb antibodies. Report

And Finally…. Stand and deliver…smiles. A new survey shows parents prefer teachers who make their children happy over teachers with high achievement ratings. Release

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.